Skip to main content

The Lure of Corporate Virtue

  • Chapter
  • First Online:
Corporate Social Responsibility and Governance

Part of the book series: CSR, Sustainability, Ethics & Governance ((CSEG))

Abstract

In this essay I explore the notion that corporations are moral agents that may aspire to virtuosity. If corporations must lose their innocence as natural moral agents do, then they too may enter a moral life cycle. Since loss of innocence may result in a sense of care about one’s behavior, one may expect corporations to manifest the affect of care. In my view the 18 corporations that made the Built-to-Last list exemplify how corporations do care about their core ideology. Using Merck and Company, Inc. as an example I discuss one way that ethicists may turn the care of corporations about their mission statement to the advantage of the entire moral community.

For those corporations that qualify as corporate persons I assume that corporate virtuosity is a good that may be publicly recognized, and it may be valuable to corporations. I also assume that corporate virtuosity is a status that is achieved over time through testing and by comparison with their peers. For instance, some corporations do seem to have the virtuosity of being in the top tier of the best places to work. Likewise when some corporations ask their shareholders to vote against a shareholder resolution on ethical conduct, management may argue that the corporation follows its own ethical code of conduct. I want to suggest that when corporations set forth ethical guidelines for behavior in their mission statement they are creating a program for the development of corporate virtuosity. How corporations respond to ethical crises and how they aspire to excellence will determine whether they are making progress toward corporate virtuosity or if not.

“Every virtue or excellence both brings into good condition the thing of which it is the excellence and makes the work of that thing be done well”

– Aristotle

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Aristotle. Edited by McKeon, R. (1941). The basic works of Aristotle. New York: Random House.

    Google Scholar 

  • Barrett, J. (2005). Can Merck survive Vioxx? Newsweek, 146(9–10), 42.

    Google Scholar 

  • Barron’s Dictionary of Finance and Investment Terms, S.v., Going-concern value.

    Google Scholar 

  • Citizens Funds’. (2004). Annual report and supplemental commentary. Portsmouth: Citizens Securities.

    Google Scholar 

  • Collins, J. C., & Porras, J. I. (1994). Built to last. New York: Harper Collins.

    Google Scholar 

  • Cox-2 selective (Includes Bextra, Celebrex, and Vioxx) and non-selective non-steriodal anti-inflammatory drugs (NSAIDs). http://www.fda.gov/cder/drug/infopage/COX2/defalult.htm

  • Fortune. (2013, May 20). Chart. F1–31.

    Google Scholar 

  • Frazier, KC. (2013). Letter to shareholders. In Merck and co. Inc. (2013) Annual report.

    Google Scholar 

  • French, P. (1979). The corporation as a moral person. American Philosophical Quarterly, 16(3), 207–215.

    Google Scholar 

  • French, P. (1992). Responsibility matters. Lawrence: University Press of Kansas.

    Google Scholar 

  • Haney, M. (2004). Corporate loss of innocence for the sake of accountability. Journal of Social Philosophy, 35(3), 391–412.

    Article  Google Scholar 

  • Merck and Co., Inc. (2005). Annual report.

    Google Scholar 

  • Merck and Company, Inc., Proxy statement for 2005.

    Google Scholar 

  • Merck and Co., Inc. (2013). Form 10-K.

    Google Scholar 

  • Mission statement. http://www.merck.com/about/mission_print.html

  • Wilson, P. E. (1993). Corporate scapegoating. Journal of Business Ethics, 12, 779–784.

    Article  Google Scholar 

  • Wilson, P. E. (1996). Sanity and irresponsibility. Philosophy, Psychiatry, Psychology, 3(4), 293–302.

    Article  Google Scholar 

  • Young, D. (2005). FDA’s drug safety initiative: Resolutions or more questions? American Journal of Health-Systems Pharmacy, 62, 1333–1336.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Paul Eddy Wilson .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Wilson, P.E. (2015). The Lure of Corporate Virtue. In: Idowu, S., Frederiksen, C., Mermod, A., Nielsen, M. (eds) Corporate Social Responsibility and Governance. CSR, Sustainability, Ethics & Governance. Springer, Cham. https://doi.org/10.1007/978-3-319-10909-1_4

Download citation

Publish with us

Policies and ethics